Recombinant Thrombomodulin Used to Successfully Treat Cronkhite-Canada Syndrome with Disseminated Intravascular Coagulation Due to Sepsis in a Compromised Patient

Recombinant thrombomodulin (rTM) was successfully used to treat a 64-year-old patient with Cronkhite-Canada Syndrome (CCS) complicated by sepsis-induced disseminated intravascular coagulation (DIC). The patient, infected with Escherichia coli, showed significant improvement with rTM therapy, which has anti-inflammatory properties and a lower risk of bleeding compared to conventional anti-coagulation agents. This case highlighted the potential effectiveness of rTM in managing severe CCS complications and suggested that rTM should be considered for severe infections and DIC in CCS patients, although further case studies are needed to establish a standard treatment protocol.